These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17850508)

  • 1. Vitiligo puzzle: the pieces fall in place.
    Westerhof W; d'Ischia M
    Pigment Cell Res; 2007 Oct; 20(5):345-59. PubMed ID: 17850508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.
    Palermo B; Campanelli R; Garbelli S; Mantovani S; Lantelme E; Brazzelli V; Ardigó M; Borroni G; Martinetti M; Badulli C; Necker A; Giachino C
    J Invest Dermatol; 2001 Aug; 117(2):326-32. PubMed ID: 11511311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The haptenation theory of vitiligo and melanoma rejection: a close-up.
    Westerhof W; Manini P; Napolitano A; d'Ischia M
    Exp Dermatol; 2011 Feb; 20(2):92-6. PubMed ID: 21255087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurogenic dysregulation, oxidative stress, autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected?
    Namazi MR
    Pigment Cell Res; 2007 Oct; 20(5):360-3. PubMed ID: 17850509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo.
    Steitz J; Wenzel J; Gaffal E; Tüting T
    Eur J Cell Biol; 2004 Dec; 83(11-12):797-803. PubMed ID: 15679123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitiligo and Hashimoto's thyroiditis: Autoimmune diseases linked by clinical presentation, biochemical commonality, and autoimmune/oxidative stress-mediated toxicity pathogenesis.
    Li D; Liang G; Calderone R; Bellanti JA
    Med Hypotheses; 2019 Jul; 128():69-75. PubMed ID: 31203913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.
    Gregg RK; Nichols L; Chen Y; Lu B; Engelhard VH
    J Immunol; 2010 Feb; 184(4):1909-17. PubMed ID: 20083666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitiligo, reactive oxygen species and T-cells.
    Glassman SJ
    Clin Sci (Lond); 2011 Feb; 120(3):99-120. PubMed ID: 20958268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
    Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
    J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitiligo: interplay between oxidative stress and immune system.
    Laddha NC; Dwivedi M; Mansuri MS; Gani AR; Ansarullah M; Ramachandran AV; Dalai S; Begum R
    Exp Dermatol; 2013 Apr; 22(4):245-50. PubMed ID: 23425123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidized tyrosinase: A possible antigenic stimulus for non-segmental vitiligo autoantibodies.
    Al-Shobaili HA; Rasheed Z
    J Dermatol Sci; 2015 Sep; 79(3):203-13. PubMed ID: 26137927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible roles of B lymphocyte activating factor of the tumour necrosis factor family in vitiligo autoimmunity.
    Lin X; Tian H; Xianmin M
    Med Hypotheses; 2011 Mar; 76(3):339-42. PubMed ID: 21075543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.
    Steitz J; Brück J; Lenz J; Büchs S; Tüting T
    J Invest Dermatol; 2005 Jan; 124(1):144-50. PubMed ID: 15654968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of experimental autoimmune vitiligo by oral administration of mushroom tyrosinase.
    Zehtab T; Yazdanparast R; Rafieii S
    Cytobios; 2001; 105(408):27-34. PubMed ID: 11368265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-196a-2 rs11614913 polymorphism is associated with vitiligo by affecting heterodimeric molecular complexes of Tyr and Tyrp1.
    Cui TT; Yi XL; Zhang WG; Wei C; Zhou FB; Jian Z; Wang G; Gao TW; Li CY; Li K
    Arch Dermatol Res; 2015 Oct; 307(8):683-92. PubMed ID: 25896941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiopathology and genetics of vitiligo.
    Passeron T; Ortonne JP
    J Autoimmun; 2005; 25 Suppl():63-8. PubMed ID: 16298511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo.
    Ben Ahmed M; Zaraa I; Rekik R; Elbeldi-Ferchiou A; Kourda N; Belhadj Hmida N; Abdeladhim M; Karoui O; Ben Osman A; Mokni M; Louzir H
    Pigment Cell Melanoma Res; 2012 Jan; 25(1):99-109. PubMed ID: 21985183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of 4-substituted phenols to induce vitiligo and antimelanoma immunity.
    Kammeyer A; Willemsen KJ; Ouwerkerk W; Bakker WJ; Ratsma D; Pronk SD; Smit NPM; Luiten RM
    Pigment Cell Melanoma Res; 2019 Jul; 32(4):540-552. PubMed ID: 30767390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
    van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
    J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.